T-cell depletion

T-cell depletion

A therapeutic manoeuvre (e.g., diphtheria toxin injection), which is meant to reduce T cells that play a key role in immune response. T-cell depletion of a donor’s bone marrow graft reduces the risk of graft versus host disease (GVHD).
References in periodicals archive ?
ATOR-1015 is a next generation CTLA-4 bispecific antibody developed for tumour -directed immunotherapy with increased capability of regulatory T-cell depletion. It is wholly-owned by Alligator.
In Japan, there has a tendency to select tacrolimus rather than cyclosporine for GVHD prophylaxis, and the cumulative incidence of chronic GVHD was higher in NHL patients with tacrolimus plus methotrexate than in those with cyclosporine plus methotrexate for GVHD prophylaxis.[24] Many research reported that chronic GVHD significantly reduced by GVHD prophylaxis accompanied with ATG.[33] However, some studies showed in vivo T-cell depletion with ATG increased lymphoma recurrence rate and early opportunistic virus infection.
Checkpoint inhibitors have been studied as treatment for chronic infectious diseases by restoring T-cell depletion (2,3,7), including PML, in which PD-1 on CD4 and CD8 cells has been reported (1,8).
ATOR-1015 is a next generation CTLA-4 bispecific antibody developed for tumour-directed immunotherapy with increased capability of regulatory T-cell depletion. ATOR-1015 binds to the checkpoint receptor CTLA-4 and the co-stimulatory receptor OX40.
T-cell depletion was associated with very high non relapse mortality (NRM) after haplo HSCT all over the world.
Cell purification procedures such as processing and selection, enable reduction of the aspirate volume and decrease of RBC quantity (depletion = 80-90%; processing), as well as CD[34.sup.+] cell enrichment (positive selection) or T-cell depletion (efficacy 3-4 Log10; negative selection) [4, 16, 26].
Knox et al., "Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections," Blood, vol.
Particularly, T-cell depletion associated with bendamustine is considered a major contributing factor to immune impairment against viral infections including CMV [8].
The method for T-cell depletion (monoclonal antibody depletion or [CD3.sup.+] selection) depended on the year in which HSCT was performed.
The 25HC also reversed the T-cell depletion caused by HIV.
One risk factor identified is T-cell depletion either ex vivo by CD34+ positive selection or in vivo with Alemtuzumab or antithymocyte globulin (ATG).
Full browser ?